Daebong LS to pass through Kosdaq preliminary review.

Published: 2005-11-04 06:57:00

Updated: 2005-11-04 06:57:00

Daebong LS announced on Oct. 27 that the preliminary review for the Kosdaq listing passed through the Kosdaq Market of the Korea Exchange, referring to Daebong's sales of 14.7 billion won in 2004 and 20% of consecutive growth during the past 3 years.

Daebong LS was founded in 1986, producing,...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK